Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Markus Magerl M.D."'
Autor:
Timothy Craig D.O., Ralph Shapiro M.D., Arthur Vegh M.D., James W. Baker M.D., Jonathan A. Bernstein M.D., Paula Busse M.D., Markus Magerl M.D., Inmaculada Martinez-Saguer M.D., Marc A. Riedl M.D., William Lumry M.D., Debora Williams-Herman M.D., Jonathan Edelman M.D., Henrike Feuersenger Ph.D., Thomas Machnig M.D., Mikhail Rojavin Ph.D.
Publikováno v:
Allergy & Rhinology, Vol 8 (2017)
Background The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-
Externí odkaz:
https://doaj.org/article/37417623447f45af92b3c0e6ec303117
Autor:
Aleena Banerji M.D., Murat Baş M.D., Jonathan A. Bernstein M.D., Isabelle Boccon-Gibod M.D., Maria Bova M.D., Ph.D., John Dempster, Anete Sevciovic Grumach M.D., Ph.D., Markus Magerl M.D., Kimberly Poarch PA-C, Manuel Branco Ferreira M.D., Ph.D.
Publikováno v:
Allergy & Rhinology, Vol 7 (2016)
Background Published literature documents the substantial burden of hereditary angioedema (HAE) with C1 inhibitor deficiency on the quality of life and work productivity of patients. However, despite advances in the field and the availability of guid
Externí odkaz:
https://doaj.org/article/b30aaad2889d4d5094757a7b59114f5f